EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

Ingredient Engine · Demonstration 1

Curcumin's solubility problem, worked through four fixes

Curcumin, the main pigment of turmeric, barely dissolves in water and breaks down at intestinal pH. This demonstration compares four formulation strategies for it: what each one physically changes, how each fails, and which experiments would tell them apart. Better solubility is a laboratory result. Only a pharmacokinetic study shows exposure, and exposure is not benefit.

Educational demonstrationCompany in formation (what exists today). Published values are cited; hypothetical inputs are labeled; nothing here is a measured EUTECNIQ result or dosing advice.

How much water would dissolve a 500 mg dose? Liters of water at three published solubility values, log scale

Water needed to dissolve a hypothetical 500 mg dose of curcuminDot plot on a logarithmic axis of liters of water. At 11 nanograms per milliliter, the solubility quoted for pH 5 buffer, dissolving 500 mg would take about 45,500 liters; at 1 microgram per milliliter about 500 liters; at 10 micrograms per milliliter about 50 liters. A copper line marks 250 milliliters, the volume used in the ICH M9 definition of a highly soluble drug. The dose number, dose divided by 250 mL times solubility, is about 182,000, 2,000 and 200.0.11101001,00010,000100,000liters of water, log scale250 mL11 ng/mLquoted for pH 5 buffer45,500 LDo ≈ 182,0001 µg/mLlow end of an estimate500 LDo ≈ 2,00010 µg/mLhigh end of an estimate50 LDo ≈ 200
Water needed to dissolve a hypothetical 500 mg dose of curcuminDot plot on a logarithmic axis of liters of water. At 11 nanograms per milliliter, the solubility quoted for pH 5 buffer, dissolving 500 mg would take about 45,500 liters; at 1 microgram per milliliter about 500 liters; at 10 micrograms per milliliter about 50 liters. A copper line marks 250 milliliters, the volume used in the ICH M9 definition of a highly soluble drug. The dose number, dose divided by 250 mL times solubility, is about 182,000, 2,000 and 200.0.1101,000100,000liters of water, log scale250 mL11 ng/mL, quoted for pH 5 buffer45,500 LDo ≈ 182,0001 µg/mL, low end of an estimate500 LDo ≈ 2,00010 µg/mL, high end of an estimate50 LDo ≈ 200
Hypothetical example Published evidence Volume = dose ÷ solubility. The 500 mg dose is hypothetical. Solubility values: 11 ng/mL as quoted for pH 5 buffer (Brotons-Canto et al. 2021); 1–10 µg/mL as estimated at neutral pH (Nelson et al. 2017). 250 mL is the volume in the ICH M9 definition of a highly soluble drug. Do is the dose number (section 02). Values as a table.

In brief · The comparative verdict

No strategy wins on solubility alone: each fixes a different limit, and only a dose-matched human PK study can rank their exposure for a product

Curcumin's dose number stays far above 1, and no particle size changes that. The four strategies act on different quantities, carry different costs for curcumin, and have different amounts of published evidence behind them.

Comparative verdict: for each strategy, what it changes, its main constraint for curcumin, the strongest curcumin evidence found and the test that would decide it
StrategyChangesMain constraint for curcuminStrongest curcumin evidence foundDeciding laboratory test
Lipid-based SNEDDSSolubilized state (no dissolution step)Capacity: about 24 g of preconcentrate for 500 mg at 21 mg/gIn vitro and animal for a self-microemulsifying system (Cui et al. 2009); no self-emulsifying human study foundIn vitro lipolysis with phase separation and solid-form check
Cyclodextrin complexApparent solubility (equilibrium)Mass: at least 3.1–3.5 g of cyclodextrin per gHuman PK: 39-fold higher total curcuminoid AUC for a γ-cyclodextrin formulation, 12 volunteers (Purpura et al. 2018)Phase-solubility diagram and dilution test
NanocrystalDissolution rate (surface area)Dose number stays far above 1Rats: 16-fold for a nanocrystal solid dispersion (Onoue et al. 2010). In humans, a colloidal nanoparticle preparation of unstated solid form gave 27-fold (Sasaki et al. 2011)Non-sink dissolution; size and form over storage
Amorphous solid dispersionSupersaturation (kinetic)Physical stability: crystallization inhibition was limitedRats: 12-fold (Onoue et al. 2010); a human study is listed in a review, but its report was not reviewedTwo-stage supersaturation test; humidity stability

Verdict: choose candidates from the families that act on the diagnosed limit, test them against preset stop rules, and rank them only with a crossover PK study against a dose-matched unformulated comparator. Fold-changes from different studies are not comparable. None of the four addresses metabolism or elimination, and all four leave dissolved curcumin exposed at intestinal pH.

Published evidence Hypothetical example Summarizes sections 04 (side by side) and 05 (evidence), with the stop rules of 06. The 500 mg dose is hypothetical. The equations behind the dose number follow in section 02.

01 · The molecule

Curcumin is lipophilic, crystalline and least stable where it dissolves best

Every property below is cited to its source. Where sources disagree, both values are shown, because the disagreement is itself a formulation fact: curcumin's solubility in water is hard to measure.

Published physicochemical properties of curcumin, with sources
PropertyPublished valueWhat it means for formulationSource
Molecular weight368.4 g/mol (C21H20O6)Sets the mass of carrier per mole of curcumin, for example in a 1:1 cyclodextrin complexPubChem CID 969516 (computed)
Lipophilicity, log PXLogP3 3.2 (computed); about 3.0 (review); calculated values 2.3–3.2A log P near 3 means about a thousandfold preference for octanol over water: lipid excipients can dissolve it where gut fluid cannotPubChem; Priyadarsini 2014; Nelson et al. 2017
Melting point183 °C (HSDB); 179–182 °C (EU food additive listing)A stable crystal: the lattice must be broken (dissolved, milled or made amorphous) before curcumin is availablePubChem, from HSDB and EU Food Improvement Agents
Solubility in water"Insoluble in water"; estimated 1–10 µg/mL at room temperature and neutral pH, "only an estimate" because curcumin aggregates; 11 ng/mL quoted for pH 5 bufferValues differ by up to a thousandfold, so a formulation decision should not rest on one literature number; it should be measured in the intended mediumPubChem (HSDB); Nelson et al. 2017; Brotons-Canto et al. 2021, quoting earlier work
Acidity constantspKa 8.38 ± 0.04, 9.88 ± 0.02 and 10.51 ± 0.01 in water (one study); a review reports ranges of 8.5–10.4 and 9.5–10.7 for the first twoNeutral below about pH 8, which covers the pH 1.2–6.8 range of ICH M9 solubility testing; the ionized form above it is more soluble and also degradesBernabé-Pineda et al. 2004; Nelson et al. 2017
Stability against pHAbout 90% decomposed within 30 min in pH 7.2 phosphate buffer at 37 °C; decomposition faster at neutral to basic pH across pH 3–10Dissolved curcumin can be lost to degradation before it is absorbed; a solubility measurement at intestinal pH can be confounded by breakdownWang et al. 1997

In an emulsion, curcumin kept best below pH 7 Curcumin retained after one month at 37 °C in oil-in-water emulsions, % (Kharat et al. 2017); dashed lines: acidity constants in water (Bernabé-Pineda et al. 2004)

Curcumin retained in an emulsion after one month at 37 °C, by pHKharat and colleagues stored curcumin in oil-in-water emulsions for one month at 37 degrees Celsius. More than 85 percent was retained under acidic conditions, below pH 7, shown as a bound. At pH 7.0, 7.4 and 8.0, 62, 60 and 53 percent was retained. Vertical lines mark the three acidity constants measured in water by Bernabe-Pineda and colleagues: 8.38, 9.88 and 10.51. Curcumin is most stable where it is least ionized and least soluble.025507510034567891011pH% retainedpKa 8.38, 9.88, 10.51 (dashed)> 85 % retained below pH 7(reported as a bound)626053pH 7.0pH 8.0
Curcumin retained in an emulsion after one month at 37 °C, by pHKharat and colleagues stored curcumin in oil-in-water emulsions for one month at 37 degrees Celsius. More than 85 percent was retained under acidic conditions, below pH 7, shown as a bound. At pH 7.0, 7.4 and 8.0, 62, 60 and 53 percent was retained. Vertical lines mark the three acidity constants measured in water by Bernabe-Pineda and colleagues: 8.38, 9.88 and 10.51. Curcumin is most stable where it is least ionized and least soluble.0255075100357911pH% retained after 1 month, 37 °CpKa 8.38, 9.88, 10.51 (dashed)> 85 % below pH 7(a bound)625360
Published evidence Kharat M, et al. J Agric Food Chem. 2017;65(8):1525–1532 (abstract values; emulsions of 30% medium-chain triglyceride, 1 mg curcumin per g oil, d32 ≈ 298 nm); the acidic result is reported as a bound, so no single pH is plotted for it. Bernabé-Pineda M, et al. Spectrochim Acta A. 2004;60(5):1091–1097.
Data table
Curcumin retained in emulsions after one month at 37 °C
Storage pHRetained, %
Below 7 (acidic conditions)> 85
7.062
7.460
8.053

The barrier is therefore twofold: too little dissolves at gut pH, and what dissolves near neutral pH degrades. A strategy that raises solubility without protecting the molecule may only move the loss to a later step.

Notes and limits

Absorption is not curcumin's only obstacle. Anand and colleagues attributed its low plasma and tissue levels to "poor absorption, rapid metabolism, and rapid systemic elimination" (Mol Pharm. 2007). A solubility fix acts on the first of these and leaves the other two in place. Nelson and colleagues report that in one dose-escalation study curcumin was detected in the serum of only 2 of 6 people given single doses of 10 or 12 g.

The 11 ng/mL figure is widely quoted for pH 5 buffer; the measurement is usually attributed to Tønnesen, Másson and Loftsson (2002), whose full text was not reviewed. The abstract of that paper reports that cyclodextrin complexation raised curcumin's water solubility at pH 5 "by a factor of at least 104".

Next: what these numbers imply for a dose

02 · The arithmetic

Smaller particles dissolve faster, but no particle size fixes the dose number

Two dimensionless numbers separate the problems. The dose number Do asks whether the fluid can hold the dose at all. The dissolution number Dn asks whether particles finish dissolving within small-intestinal transit, assuming the fluid never saturates.

Dose number and dissolution number for crystalline curcumin Hypothetical example

1 to 5,000 mg. 500 mg is the curcuminoid dose of one human study (Schiborr et al. 2014); not a recommendation.

Published values; see section 01.

Log scale, 0.1 to 100 µm. One size for all particles.

Dose number Do
2,000
Water to dissolve the dose
500L
Dissolution number Dn
0.024
Time for one particle to dissolve, sink
5.81days

Both dissolution rate and solubility limit this case. Particles of this size would not finish dissolving within transit even in unlimited fluid, and 250 mL could hold only about 0.05% of the dose.

Dissolution number against particle diameter Log–log; one line per published solubility; the hollow marker follows the calculator

Dissolution number against particle diameter at three published solubility valuesLog-log plot. The dissolution number Dn equals 3 D Cs T over r squared rho, with D 5 times 10 to the minus 6 square centimeters per second, rho 1.2 grams per cubic centimeter and a small-intestinal transit time of 199 minutes. Each solubility gives a straight line falling with the square of the diameter. A copper line marks Dn equal to 1. At 11 nanograms per milliliter, Dn reaches 1 at about 0.8 micrometers; at 1 microgram per milliliter at about 7.7 micrometers; at 10 micrograms per milliliter at about 24 micrometers. Three hypothetical diameters are marked: 50, 5 and 0.25 micrometers.10⁻⁵10⁻⁴10⁻³10⁻²0.111010010³10⁴10⁵0.1110100particle diameter, µm (log)Dn11 ng/mL1 µg/mL10 µg/mLDn = 150 µm5 µm0.25 µm
Dissolution number against particle diameter at three published solubility valuesLog-log plot. The dissolution number Dn equals 3 D Cs T over r squared rho, with D 5 times 10 to the minus 6 square centimeters per second, rho 1.2 grams per cubic centimeter and a small-intestinal transit time of 199 minutes. Each solubility gives a straight line falling with the square of the diameter. A copper line marks Dn equal to 1. At 11 nanograms per milliliter, Dn reaches 1 at about 0.8 micrometers; at 1 microgram per milliliter at about 7.7 micrometers; at 10 micrograms per milliliter at about 24 micrometers. Three hypothetical diameters are marked: 50, 5 and 0.25 micrometers.10⁻⁴10⁻²110010⁴0.1110100particle diameter, µm (log)Dn, dissolution number (log)Dn = 111 ng/mL1 µg/mL10 µg/mL5050.25
Hypothetical example Computed from Amidon's dissolution number with the default inputs given by Abuhassan et al. 2022 (D = 5 × 10⁻⁶ cm²/s, ρ = 1.2 g/cm³, transit 199 min). Dashed verticals: hypothetical 50, 5 and 0.25 µm particles. Above the copper line, particles could dissolve within transit if the fluid stayed unsaturated.
Method, assumptions and limits
What it calculates
The dose number, the volume of water that would dissolve the dose, the dissolution number and the time for one particle to dissolve under sink conditions.
Equations
Do = (M0/V0)/Cs with V0 = 250 mL; volume = M0/Cs; Dn = 3D CsTsi/(r²ρ); dissolution time = Tsi/Dn = r²ρ/(3D Cs).
Variables and units
M0 dose, mg; Cs solubility, converted from µg/mL to mg/mL and g/cm³; r particle radius (half the diameter), cm; D = 5 × 10⁻⁶ cm²/s; ρ = 1.2 g/cm³; Tsi = 199 min.
Assumptions
Spherical particles of one size; sink conditions for Dn (the dissolved concentration stays far below Cs); no degradation, no micellar solubilization by bile, no supersaturation, no change of Cs with particle size.
Valid range
A screening estimate. When Do is far above 1 the sink assumption fails within minutes, so a large Dn then says the rate is not the limit; it does not say the dose dissolves. Real gut water volumes are smaller than 250 mL (see Bioavailability by design).
What it does not establish
Absorption, exposure or benefit of any product. The D and ρ values are generic defaults, not measured for curcumin.
Verification
An independent reference calculation reproduces every readout for the nine cases in the table below.

Amidon GL, et al. Pharm Res. 1995;12(3):413–420; Abuhassan Q, et al. Eur J Pharm Biopharm. 2022;170:160–169 (equation forms and default values); ICH M9 (2019), 250 mL. Noyes–Whitney background: Dokoumetzidis A, Macheras P. Int J Pharm. 2006;321:1–11.

Table: the nine reference cases (500 mg, hypothetical)
Dose number, water volume and dissolution number for three solubility values and three hypothetical particle diameters
SolubilityDoWater for 500 mgDn at 50 µmDn at 5 µmDn at 0.25 µm
11 ng/mL182,00045,500 L0.000260.02610.5
1 µg/mL2,000500 L0.0242.4955
10 µg/mL20050 L0.2423.99,550

Milling curcumin to 0.25 µm moves Dn above 1 at every published solubility, while Do stays between 200 and 182,000. The limit is how much the fluid can hold. Strategies that keep curcumin dissolved in a carrier, or hold it above its crystalline solubility for a time, act on that limit; size reduction alone does not.

Next: the four strategies

03 · Four strategies

Each strategy changes a different quantity, and each fails in its own way

Choose a strategy to see its mechanism, what it changes, its constraints, how it fails and the experiments that would confirm it. Each panel ends with the curcumin evidence by level; in vitro, animal and human pharmacokinetic (PK) results answer different questions, and section 05 sets them side by side.

Lipid-based self-nanoemulsifying system (SNEDDS): dissolve curcumin first, then keep it dissolved

Lipid-based self-emulsifying system: dissolve first, then keep it dissolvedFour steps drawn top to bottom. A capsule-shaped preconcentrate holds curcumin dissolved in oil, surfactant and cosolvent. On dilution in gut fluid fine oil droplets form with curcumin inside. Lipase at the droplet surface digests the oil and, with bile, mixed micelles carry curcumin. If dilution or digestion removes solvent capacity, curcumin precipitates as crystals, drawn in copper. Not to scale.1Preconcentratecurcumin dissolved in oil,surfactant and cosolvent2Dilution in gut fluidfine oil droplets form;curcumin stays insidethem3Digestionlipase (wedge) splits theoil; with bile, mixedmicelles carry curcumin!Failure: precipitationdilution or digestionremoves solvent capacityand curcumin crystallizes
Educational schematic Not to scale. After Pouton 2006 and Williams et al. 2013.

What it changes: the form in which curcumin arrives. It is already dissolved in oil, surfactant and cosolvent, and stays dissolved only while droplets, and after digestion mixed micelles, can hold it. Its aqueous solubility is unchanged.

Loading and excipient burden
Capped by solubility in the preconcentrate. One self-microemulsifying system dissolved 21 mg of curcumin per gram (Cui et al. 2009); at that capacity a hypothetical 500 mg dose would need about 24 g of preconcentrate. That system was 57.5% surfactant, 30% PEG 400 and 12.5% oil.
Dilution and digestion
Surfactant- and cosolvent-rich systems can lose solvent capacity as they are diluted and digested. In standardized digestion tests, drugs crystallized from medium-chain and surfactant-only formulations only when the calculated maximum supersaturation ratio exceeded 3 (Williams et al. 2013, with fenofibrate and tolfenamic acid).
Physical and chemical stability
Curcumin in an emulsion still degraded at pH 7 and above (Kharat et al. 2017); the oil phase can oxidize; each excipient's status for a food or supplement must be checked separately from its use in medicines.

Typical failure modes: precipitation after dilution or digestion; a dose too large for the capsule volume; chemical loss of curcumin in the aqueous phase.

Confirmatory experiments: solubility in candidate oils, surfactants and cosolvents; dispersion at several dilutions with droplet size; in vitro lipolysis with curcumin measured in the aqueous phase and in the pellet, and X-ray powder diffraction of the pellet; stability-indicating HPLC; then a human PK study.

Curcumin evidence: in vitro and animal (rat in situ, mouse oral) for a self-microemulsifying system (Cui et al. 2009); no human study of a self-emulsifying system found. Details

Cyclodextrin inclusion complex: raise the apparent solubility through an equilibrium

Cyclodextrin inclusion complex: raise the apparent solubility through an equilibriumTop: a gamma-cyclodextrin ring drawn to scale in cross-section through its axis, 1.75 nanometers across and 0.79 nanometers high, around a cavity 0.75 to 0.83 nanometers wide; a dashed copper outline marks the space a guest segment would occupy; no molecular structure is drawn. Middle: the equilibrium drug plus cyclodextrin forms the complex with a 1 to 1 stability constant; dilution or a competing guest releases free drug. Bottom: a schematic phase-solubility diagram, total dissolved drug rising linearly from the intrinsic solubility S zero with a slope below 1; complexation efficiency equals slope over one minus slope, which equals K times S zero.γ-Cyclodextrin, cut through its ring axis1.75 nm0.79 nm highcavity 0.75–0.83Dashed copper: the space a guest segmentwould fill; no structure drawnD + CDD/CDK₁:₁The complex is an equilibrium. Dilution or acompeting guest releases free curcumin.S₀cyclodextrin concentrationtotal dissolvedstraight line, slope < 1CE = slope / (1 − slope) = K₁:₁ · S₀
Educational schematic Ring drawn to scale from Păduraru et al. 2022, Table 1; the phase-solubility plot is a schematic of the relation given by Saokham et al. 2018.

What it changes: the apparent solubility, meaning free plus complexed curcumin. The complex is in dynamic equilibrium with free drug, and drug is "readily released from the complex upon media dilution or by competitive complexation" (Saokham et al. 2018). For curcumin, complexation raised water solubility at pH 5 by at least 104 and strongly improved hydrolytic stability under alkaline conditions, while photodecomposition was faster than in an organic-solvent solution (Tønnesen et al. 2002).

Loading and excipient burden
At least one cyclodextrin per curcumin in a 1:1 complex: 1,135 g/mol for β-cyclodextrin and 1,297 g/mol for γ-cyclodextrin against 368.4 g/mol for curcumin, or 3.1 and 3.5 g per g. A hypothetical 500 mg dose would carry at least 1.5 or 1.8 g of cyclodextrin before any excess. "The formulation bulk usually limits the amount of CD that can be included in solid dosage forms."
Dilution and competition
Dilution and competing molecules in the gut release the drug, which is the intended release route and also a precipitation risk if free curcumin exceeds its own solubility. Large cyclodextrin excess can hamper release.
Physical stability
Complexes of the natural cyclodextrins can self-assemble into aggregates and have limited solubility (Saokham et al. 2018). Because curcumin's intrinsic solubility is uncertain, the complexation efficiency (from the slope) is more reliable than the stability constant.

Typical failure modes: low complexation efficiency and a large serving; a physical mixture mistaken for a complex; photodegradation in the dissolved state.

Confirmatory experiments: phase-solubility diagram at the relevant pH; solid-state evidence that a complex formed rather than a physical mixture; dissolution and dilution testing; stability under light and at intestinal pH; then a human PK study.

Curcumin evidence: in vitro (Tønnesen et al. 2002) and human PK, 39-fold total curcuminoids for one γ-cyclodextrin formulation (Purpura et al. 2018). Details

Nanocrystal: raise the dissolution rate by raising surface area

Nanocrystal: raise the dissolution rate by raising surface areaTop: one large particle and many small particles of the same mass; surface per gram scales with one over the diameter, so going from 50 to 0.25 micrometers, both hypothetical, gives 200 times more surface. Middle: a crystal coated with a stabilizer, surrounded by a dashed diffusion layer of thickness h; an inset shows concentration falling from the solubility Cs at the surface to the bulk concentration. The Noyes-Whitney form dM/dt equals D times A times Cs minus C over h: smaller particles raise A, the surface, while Cs barely changes. Bottom, in copper: Ostwald ripening and aggregation make particles grow. Not to scale.Same mass, smaller particlessurface pergram risesas 1/d50 → 0.25 µm (hypothetical): 200× surfacecrystal + stabilizer (ticks)diffusion layer hCsC bulkdistancedM/dt = D · A · (Cs − C) / hSmaller particles raise A, the surface, so therate rises; Cs, the solubility, barely moves.Failure: Ostwald ripeningand aggregation makeparticles grow
Educational schematic Not to scale. Rate law: Noyes–Whitney form, as reviewed by Dokoumetzidis and Macheras 2006; instability mechanisms after Li et al. 2021.

What it changes: the dissolution rate, through surface area per gram. Below about 1 µm the saturation solubility also rises as size falls (the Ostwald–Freundlich relation, Li et al. 2021), but the particle remains crystalline and the fluid's capacity stays near the crystalline value. Section 02 shows the consequence for curcumin: Dn can exceed 1 while Do stays far above 1.

Loading and excipient burden
Low compared with carriers: the particle is the drug crystal, coated with a stabilizer. Drug nanocrystals "usually require the addition of stabilizers such as polymers or surfactants" (Li et al. 2021).
Dilution and the gut
Electrostatic stabilization "may be destroyed due to the influence of electrolytes in gastrointestinal fluids" (Li et al. 2021). Dissolved curcumin is then exposed to the same pH-dependent degradation as any other form.
Physical stability
Small particles have high surface energy, which drives aggregation, sedimentation and Ostwald ripening; redispersibility after drying is a key factor for solid products (Li et al. 2021).

Typical failure modes: particle growth in storage; aggregation in gut fluid; incomplete redispersion of a dried powder; a gain in rate that the dose number makes irrelevant.

Confirmatory experiments: particle size by laser diffraction and dynamic light scattering over storage; X-ray powder diffraction and calorimetry to confirm the crystal form is kept; size and charge in biorelevant media; non-sink dissolution; then a human PK study.

Curcumin evidence: rats, 16-fold for a nanocrystal solid dispersion (Onoue et al. 2010); human PK for a colloidal nanoparticle preparation of unstated crystallinity, 27-fold (Sasaki et al. 2011). Details

Amorphous solid dispersion: remove the crystal lattice to create supersaturation

Amorphous solid dispersion: remove the crystal lattice to create supersaturationTop left: crystalline curcumin drawn as an ordered lattice. Top right: an amorphous solid dispersion with drug molecules scattered among wavy polymer chains. A copper arrow back to the crystal marks the storage failure: moisture lowers the glass transition temperature and the drug recrystallizes. Bottom: a schematic of dissolved concentration against time with a copper line at the crystalline solubility. One dashed curve rises above it and stays above it where a polymer inhibits precipitation; another rises and falls back to it as the drug precipitates. Not to scale.CrystalAmorphousFailure in storage: moisture lowers Tg andthe drug recrystallizesIn the gut: supersaturate, then holdcrystalline solubilitypolymer inhibits precipitationprecipitatesCtime
Educational schematic Not to scale. After Brouwers et al. 2009 and Bhujbal et al. 2021.

What it changes: the energy of the solid. Curcumin is dispersed in a polymer glass without a crystal lattice, so dissolution can produce concentrations above the crystalline solubility. Supersaturating systems must then "be stabilized to allow for significant absorption", for example with precipitation inhibitors (Brouwers et al. 2009). The gain is kinetic and lasts only until the drug crystallizes.

Loading and excipient burden
Limited by how much drug the polymer holds in one phase, which depends on drug, polymer and process (Bhujbal et al. 2021). At a hypothetical 20% drug loading, 500 mg of curcumin would come in 2.5 g of dispersion.
Dilution and the gut
The supersaturated solution can precipitate after dissolution; whether the polymer holds it depends on the polymer, the dose and the medium (Brouwers et al. 2009).
Physical stability
Moisture lowers the glass transition temperature and raises the risk of crystallization; amorphous–amorphous phase separation can also undo the advantage (Bhujbal et al. 2021). For curcumin, polymers inhibited crystallization, but most were "not highly effective" in long-term storage, which the authors linked to curcumin's intramolecular hydrogen bonding (Wegiel et al. 2014).

Typical failure modes: recrystallization in storage, especially in humidity; phase separation; precipitation in the gut after supersaturation; degradation of the dissolved drug.

Confirmatory experiments: X-ray powder diffraction and calorimetry (crystallinity, glass transition) under accelerated temperature and humidity; infrared evidence of drug–polymer interaction; non-sink, two-stage (gastric to intestinal pH) dissolution with supersaturation and precipitation followed over time; stability-indicating HPLC; then a human PK study.

Curcumin evidence: in vitro storage stability (Wegiel et al. 2014) and rats, 12-fold (Onoue et al. 2010); a human study is listed in a systematic review, but its report was not reviewed. Details

Pouton CW. Eur J Pharm Sci. 2006;29:278–287; Williams HD, et al. Pharm Res. 2013;30(12):3059–3076; Cui J, et al. Int J Pharm. 2009;371:148–155; Saokham P, et al. Molecules. 2018;23(5):1161; Păduraru DN, et al. Pharmaceutics. 2022;14(8):1748; Tønnesen HH, et al. Int J Pharm. 2002;244:127–135 (abstract); Müller RH, et al. Eur J Pharm Biopharm. 2011;78:1–9; Li J, et al. Drug Deliv. 2021;28(1):19–36; Brouwers J, et al. J Pharm Sci. 2009;98(8):2549–2572; Bhujbal SV, et al. Acta Pharm Sin B. 2021;11(8):2505–2536; Wegiel LA, et al. Pharm Dev Technol. 2014;19(8):976–986; Kharat M, et al. 2017.

Next: the four side by side

04 · Side by side

The quantity a strategy changes decides which test can show it worked

Four strategies compared: the quantity changed, the main constraint, the typical failure and the deciding laboratory test
StrategyChangesMain constraint for curcuminTypical failureDeciding laboratory test
Lipid-based SNEDDSSolubilized state (no dissolution step)Capacity: about 24 g of preconcentrate for 500 mg at 21 mg/gPrecipitation on dilution or digestionIn vitro lipolysis with phase separation and solid-form check
Cyclodextrin complexApparent solubility (equilibrium)Mass: at least 3.1–3.5 g of cyclodextrin per gLow complexation efficiency; bulkPhase-solubility diagram and dilution test
NanocrystalDissolution rate (surface area)Dose number stays far above 1Particle growth, aggregationNon-sink dissolution; size and form over storage
Amorphous solid dispersionSupersaturation (kinetic)Physical stability: crystallization inhibition was limitedRecrystallization; precipitation in the gutTwo-stage supersaturation test; humidity stability

None of the four addresses metabolism or elimination, and all four leave dissolved curcumin exposed at intestinal pH. These are reasons to measure degradation products alongside dissolved curcumin in every test.

Next: what curcumin studies have shown

05 · Published evidence for curcumin

Human exposure data exist for some strategies and are missing or not yet reviewed for others

Each cell names the cited study and what it measured. Fold-changes from different studies are not comparable: they differ in comparator, dose, analyte (free curcumin or total curcuminoids after hydrolysis) and species.

Curcumin-specific published evidence for each strategy, by evidence level
StrategyIn vitroAnimalHuman pharmacokinetics
Lipid-based (self-microemulsifying)Droplets about 21 nm on dilution; more than 95% dissolved in 20 min at pH 1.2 or 6.8, against less than 2% of crude curcumin in 60 min (Cui et al. 2009)Absorption by passive diffusion in rat intestine in situ; significantly higher oral absorption than a suspension in mice (Cui et al. 2009)No self-emulsifying study found. A systematic review lists a microemulsion among five systems tested in healthy volunteers (Pan-On et al. 2022); its report was not reviewed. A liquid micellar formulation, a different system, gave 185-fold higher total curcuminoid AUC (Schiborr et al. 2014)
CyclodextrinWater solubility at pH 5 raised at least 104-fold; alkaline hydrolytic stability improved; photodecomposition faster (Tønnesen et al. 2002)None foundγ-Cyclodextrin formulation: 39-fold higher total curcuminoid AUC0–12 h than unformulated extract; 12 volunteers, double-blind crossover (Purpura et al. 2018)
Nanocrystal or particle-size reductionMarked improvement in dissolution against crystalline curcumin; high photochemical stability as a solid (Onoue et al. 2010)Nanocrystal solid dispersion: 16-fold higher oral bioavailability in rats (Onoue et al. 2010)Colloidal nanoparticle preparation: 27-fold higher AUC at 30 mg (Sasaki et al. 2011; the abstract does not state whether the particles are crystalline). Micronized powder: 9-fold (Schiborr et al. 2014)
Amorphous solid dispersionPolymers inhibited crystallization, with limited long-term effect (Wegiel et al. 2014)12-fold higher oral bioavailability in rats (Onoue et al. 2010)A systematic review lists a solid dispersion among five systems tested in healthy volunteers (Pan-On et al. 2022); that study's report was not reviewed, so no number is quoted

The one study that compared three of the strategies side by side, in rats, ranked the nanocrystal solid dispersion (16-fold), the amorphous dispersion (12-fold) and a nanoemulsion (9-fold) against crystalline curcumin (Onoue et al. 2010). A rank order in one animal study is a hypothesis for a human study, not a result for a product.

Why fold-changes are hard to compare

Many curcumin studies treated plasma with glucuronidase and sulfatase before analysis, so they report conjugated metabolites together with free curcumin; Stohs and colleagues call this "widely used but inappropriate". Comparators differ (crystalline powder, standardized extract), doses differ and must be normalized on an assumption of proportionality, and sex alone changed one micellar result from 114-fold in men to 277-fold in women (Schiborr et al. 2014). A worked comparison is on Bioavailability by design.

Cui J, et al. 2009; Tønnesen HH, et al. 2002; Purpura M, et al. Eur J Nutr. 2018;57(3):929–938; Onoue S, et al. J Pharm Sci. 2010;99(4):1871–1881 (Sprague-Dawley rats); Sasaki H, et al. Biol Pharm Bull. 2011;34(5):660–665; Schiborr C, et al. Mol Nutr Food Res. 2014;58(3):516–527; Wegiel LA, et al. 2014; Pan-On S, et al. J Control Release. 2022;348:335–345; Stohs SJ, et al. Molecules. 2020;25(6):1397.

Next: how EUTECNIQ would decide

06 · How EUTECNIQ proposes to decide

Four checkpoints, each with a stop rule written before the work starts

EUTECNIQ would choose between strategies with preset acceptance limits and would stop a candidate at the first checkpoint it fails. Human studies would be run by qualified clinical partners under ethics approval. Proposed capability

  1. 1

    Screen

    Verify the molecule's properties and compute Do and Dn. Map stability against pH and check each candidate excipient's status for the intended product category. Fix the dose and format.

    Stop if no lawful excipient set can carry the dose in an acceptable serving.

  2. 2

    Prototype

    Build two to four candidates, only from families that act on the diagnosed limit; confirm loading, solid form and assay for each.

    Stop if loading falls short of what the dose needs, or the intended form (complex, amorphous, crystalline) is not confirmed.

  3. 3

    Dispersion and digestion tests

    Run a dilution series, two-stage non-sink dissolution, and in vitro lipolysis for lipid systems or static digestion (INFOGEST, which its authors state is "not suitable for simulating digestion kinetics"). Measure dissolved curcumin, precipitate form and degradation products together, and test storage stability.

    Stop if precipitation, degradation or physical change exceeds the preset limits.

  4. 4

    PK plan with a partner

    A crossover design against a dose-matched unformulated comparator, with free curcumin and its conjugates measured separately by a validated method and the sample size justified in advance.

    Result: exposure for that formulation against that comparator. Benefit needs an outcome study.

  • Higher apparent solubility does not by itself mean higher absorption.
  • Small droplets or particles do not by themselves show higher systemic exposure.
  • Bioaccessibility in vitro is not systemic bioavailability.
  • Higher plasma curcuminoids do not show benefit.
  • One product's PK study is not evidence for another product.

Brodkorb A, et al. Nat Protoc. 2019;14:991–1014; Stohs SJ, et al. 2020. Gate structure: EUTECNIQ proposal; see the platform plan and Advanced delivery.

Working on an ingredient that will not dissolve?

Share the molecule's known properties, the intended dose and the product category. EUTECNIQ is in formation and would respond with a proposed screen and the evidence each gate would produce.

07 · Sources

Sources cited in this demonstration

Reviewed November 1, 2026: full text where noted, otherwise the PubMed abstract. All entries also appear on the Sources page.

Show the 30 sources
  1. PubChem Compound Summary, Curcumin (CID 969516): molecular weight and XLogP3 (computed); melting point from HSDB and EU Food Improvement Agents; "Insoluble in water" (HSDB). pubchem.ncbi.nlm.nih.gov/compound/969516
  2. Priyadarsini KI. The chemistry of curcumin: from extraction to therapeutic agent. Molecules. 2014;19(12):20091–20112 (full text). doi:10.3390/molecules191220091
  3. Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60(5):1620–1637 (full text). doi:10.1021/acs.jmedchem.6b00975
  4. Brotons-Canto A, González-Navarro CJ, Gil AG, et al. Zein nanoparticles improve the oral bioavailability of curcumin in Wistar rats. Pharmaceutics. 2021;13(3):361 (full text; quotes 11 ng/mL at pH 5). doi:10.3390/pharmaceutics13030361
  5. Bernabé-Pineda M, Ramírez-Silva MT, Romero-Romo M, González-Vergara E, Rojas-Hernández A. Determination of acidity constants of curcumin in aqueous solution and apparent rate constant of its decomposition. Spectrochim Acta A Mol Biomol Spectrosc. 2004;60(5):1091–1097. doi:10.1016/S1386-1425(03)00342-1
  6. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997;15(12):1867–1876. doi:10.1016/s0731-7085(96)02024-9
  7. Kharat M, Du Z, Zhang G, McClements DJ. Physical and chemical stability of curcumin in aqueous solutions and emulsions: impact of pH, temperature, and molecular environment. J Agric Food Chem. 2017;65(8):1525–1532. doi:10.1021/acs.jafc.6b04815
  8. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818. doi:10.1021/mp700113r
  9. Tønnesen HH, Másson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm. 2002;244(1–2):127–135 (abstract only). doi:10.1016/s0378-5173(02)00323-x
  10. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification. Pharm Res. 1995;12(3):413–420. doi:10.1023/A:1016212804288
  11. Abuhassan Q, Khadra I, Pyper K, Augustijns P, Brouwers J, Halbert GW. Fasted intestinal solubility limits and distributions applied to the biopharmaceutics and developability classification systems. Eur J Pharm Biopharm. 2022;170:160–169. doi:10.1016/j.ejpb.2021.12.006
  12. ICH M9. Biopharmaceutics Classification System-Based Biowaivers. Adopted November 20, 2019. database.ich.org
  13. Dokoumetzidis A, Macheras P. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm. 2006;321(1–2):1–11. doi:10.1016/j.ijpharm.2006.07.011
  14. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3–4):278–287. doi:10.1016/j.ejps.2006.04.016
  15. Williams HD, Sassene P, Kleberg K, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3. Pharm Res. 2013;30(12):3059–3076. doi:10.1007/s11095-013-1038-z
  16. Cui J, Yu B, Zhao Y, et al. Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm. 2009;371(1–2):148–155. doi:10.1016/j.ijpharm.2008.12.009
  17. Saokham P, Muankaew C, Jansook P, Loftsson T. Solubility of cyclodextrins and drug/cyclodextrin complexes. Molecules. 2018;23(5):1161 (full text). doi:10.3390/molecules23051161
  18. Păduraru DN, Niculescu AG, Bolocan A, et al. An updated overview of cyclodextrin-based drug delivery systems for cancer therapy. Pharmaceutics. 2022;14(8):1748 (Table 1). doi:10.3390/pharmaceutics14081748
  19. Purpura M, Lowery RP, Wilson JM, et al. Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. Eur J Nutr. 2018;57(3):929–938. doi:10.1007/s00394-016-1376-9
  20. Müller RH, Gohla S, Keck CM. State of the art of nanocrystals. Eur J Pharm Biopharm. 2011;78(1):1–9. doi:10.1016/j.ejpb.2011.01.007
  21. Li J, Wang Z, Zhang H, Gao J, Zheng A. Progress in the development of stabilization strategies for nanocrystal preparations. Drug Deliv. 2021;28(1):19–36 (full text). doi:10.1080/10717544.2020.1856224
  22. Onoue S, Takahashi H, Kawabata Y, et al. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J Pharm Sci. 2010;99(4):1871–1881. doi:10.1002/jps.21964
  23. Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660–665. doi:10.1248/bpb.34.660
  24. Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res. 2014;58(3):516–527. doi:10.1002/mnfr.201300724
  25. Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98(8):2549–2572. doi:10.1002/jps.21650
  26. Bhujbal SV, Mitra B, Jain U, et al. Pharmaceutical amorphous solid dispersion: a review of manufacturing strategies. Acta Pharm Sin B. 2021;11(8):2505–2536 (full text). doi:10.1016/j.apsb.2021.05.014
  27. Wegiel LA, Zhao Y, Mauer LJ, Edgar KJ, Taylor LS. Curcumin amorphous solid dispersions: the influence of intra and intermolecular bonding on physical stability. Pharm Dev Technol. 2014;19(8):976–986. doi:10.3109/10837450.2013.846374
  28. Pan-On S, Dilokthornsakul P, Tiyaboonchai W. Trends in advanced oral drug delivery system for curcumin: a systematic review. J Control Release. 2022;348:335–345. doi:10.1016/j.jconrel.2022.05.048
  29. Stohs SJ, Chen O, Ray SD, Ji J, Bucci LR, Preuss HG. Highly bioavailable forms of curcumin and promising avenues for curcumin-based research and application: a review. Molecules. 2020;25(6):1397. doi:10.3390/molecules25061397
  30. Brodkorb A, Egger L, Alminger M, et al. INFOGEST static in vitro simulation of gastrointestinal food digestion. Nat Protoc. 2019;14:991–1014. doi:10.1038/s41596-018-0119-1

Health information notice. These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice.

Read the full notice

The information is for general education only. It does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed. Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to start a development project?

Tell us about an ingredient you want to specify, verify or license. Questions? Email [email protected]